Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.44 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.44 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 4/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.40 |
| ▸ | DPP4 | P27487 | 2/20 | 0.38 |
| ▸ | DHODH | Q02127 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23639040 | 1.00 | TAS1R3 (0.44) | TAS1R3TAS1R1TAS1R2KDM1AMAOB | |
| SCHEMBL23140797 | 0.86 | TAS1R3 (0.43) | TAS1R3TAS1R1TAS1R2HCRTR2SCN9A | |
| SCHEMBL21306626 | 0.86 | MAOB (0.42) | TAS1R3TAS1R1TAS1R2KDM1AMAOB | |
| SCHEMBL29481962 | 0.86 | MAOB (0.42) | TAS1R3TAS1R1TAS1R2KDM1AMAOB | |
| SCHEMBL21294962 | 0.86 | MAOB (0.42) | TAS1R3TAS1R1TAS1R2KDM1AMAOB | |
| SCHEMBL20063742 | 0.86 | MAOB (0.42) | TAS1R3TAS1R1TAS1R2KDM1AMAOB | |
| SCHEMBL29481964 | 0.86 | MAOB (0.42) | TAS1R3TAS1R1TAS1R2KDM1AMAOB | |
| SCHEMBL31433447 | 0.84 | SCN9A (0.51) | TAS1R3TAS1R1TAS1R2KDM1AMAOB | |
| SCHEMBL23639065 | 0.84 | SCN9A (0.51) | TAS1R3TAS1R1TAS1R2KDM1AMAOB | |
| SCHEMBL23140838 | 0.76 | NOTUM (0.40) | TAS1R3TAS1R1TAS1R2HCRTR2FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115576-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2025-04-10 | — | — | US | disclosed |
| US-12209075-B2 | Pyridine-sulfonamide derivatives as sodium channel inhibitors | GENENTECH, INC. (US) | 2025-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12209075-B2 | Pyridine-sulfonamide derivatives as sodium channel inhibitors | SCN1B, CACNA1A, SCN1A | TAS1R3 254/4885TAS1R1 266/4885TAS1R2 255/4885 |
| US-20250115576-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | F12, REN, ZYX | TAS1R3 2698/4885TAS1R1 2258/4885TAS1R2 2679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.